Pharmaceuticals

Ipsen commits about $1B to acquire Simcere’s China preclinical ADC program

Ipsen is investing roughly $1 billion to secure Simcere's China-based preclinical ADC program, aiming to accelerate oncology R&D and expand its commercial footprint in Asia.

Eli Lilly’s retatrutide shows strong weight loss and eases knee pain in late-stage trial

Eli Lilly’s retatrutide produced notable weight loss and eased knee pain in a late-stage trial, reinforcing the drugmaker’s obesity strategy alongside Zepbound and an oral candidate.

Eli Lilly Lowers Cash Price for Zepbound Vials on Direct Sales Site

Eli Lilly lowers cash prices for Zepbound vials on its direct-to-consumer site, following recent White House agreements aimed at expanding U.S. access to GLP-1 therapies.